secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABEONA THERAPEUTICS INC. (ABEO)
CIK:        0000318306
Form:       8-K
Filed at:   2024-03-18T23:59:59+00:00
Accession:  0001493152-24-010206
Event type: regulatory
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abeona Therapeutics reports FY2023 results; FDA completes pz-cel PLI with Form 483, PDUFA May 25, 2024
--------------------------------------------------------------------------------

- FDA completed Pre-License Inspection of Cleveland manufacturing facility; Form 483 issued for process controls; company submitted response.
- Clinical site inspections (Stanford, UMass) for Phase 3 VIITAL study completed with no Form 483 observations.
- Net loss $54.2M ($2.53 per share) for FY2023; revenue $3.5M from Taysha license milestone.
- Cash and investments $52.6M at Dec 31, 2023; received $20M tranche from $50M Avenue credit facility in Jan 2024.
- Cash runway estimated into Q1 2025, excluding potential pz-cel commercial revenue or PRV sale.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318306/000149315224010206/0001493152-24-010206-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318306/000149315224010206/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-010206

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer